Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: PERSERIS
Published 2025-12-23 · Last reviewed 2025-12-30 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Perseris is a monthly subcutaneous long-acting risperidone formulation used for schizophrenia maintenance.
Pharmacology mirrors risperidone/paliperidone-class D2/5-HT2A blockade: prolactin elevation and EPS can be limiting, and metabolic monitoring remains important.
Perseris has a distinct absorption profile with two peaks after each injection (early hours and again around 10–14 days). Label describes an apparent terminal half-life of risperidone of ~9–11 days, driven largely by depot release rather than hepatic clearance.
For depot comparisons and planning across antipsychotics, see the LAI Navigator and the compare tool.
Perseris is often chosen when a monthly visit is feasible and clinicians prefer a subcutaneous option that does not typically require the multi- week oral overlap needed for risperidone microspheres (Consta). Practical constraints include injection-site reactions, prolactin/EPS monitoring, and the need for clinic training on the kit preparation.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Risperidone antagonizes dopamine D2 and serotonin 5-HT2A receptors with additional activity at α1-adrenergic and histamine H1 receptors.
D2 blockade supports antipsychotic effects but contributes to prolactin elevation and EPS risk, especially at higher doses.